GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » Book Value per Share

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Book Value per Share : $1.79 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals Book Value per Share?

NGM Biopharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was $1.79.

During the past 12 months, NGM Biopharmaceuticals's average Book Value Per Share Growth Rate was -43.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of NGM Biopharmaceuticals was -13.70% per year. The lowest was -23.30% per year. And the median was -18.50% per year.

NGM Biopharmaceuticals's current price is $1.54. Its book value per share for the quarter that ended in Dec. 2023 was $1.79. Hence, today's PB Ratio of NGM Biopharmaceuticals is 0.86.

During the past 8 years, the highest P/B Ratio of NGM Biopharmaceuticals was 7.78. The lowest was 0.29. And the median was 3.48.


NGM Biopharmaceuticals Book Value per Share Historical Data

The historical data trend for NGM Biopharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGM Biopharmaceuticals Book Value per Share Chart

NGM Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 4.94 3.97 4.31 3.17 1.79

NGM Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.17 2.69 2.32 2.05 1.79

Competitive Comparison of NGM Biopharmaceuticals's Book Value per Share

For the Biotechnology subindustry, NGM Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGM Biopharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NGM Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where NGM Biopharmaceuticals's PB Ratio falls into.



NGM Biopharmaceuticals Book Value per Share Calculation

NGM Biopharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(148.64-0.00)/82.91
=1.79

NGM Biopharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(148.64-0.00)/82.91
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


NGM Biopharmaceuticals  (NAS:NGM) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


NGM Biopharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Executives
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich officer: Principal Accounting Officer C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen director, officer: Chief Scientific Officer 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse director, officer: CEO and acting CFO 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Headlines

From GuruFocus

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

By GuruFocusNews GuruFocusNews 07-03-2022

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

By GuruFocusNews GuruFocusNews 07-03-2022

NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-12-2023

RHO CAPITAL PARTNERS INC Cuts Portfolio Down to Size in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-04-2022